Cargando…

PARP Inhibition Increases the Response to Chemotherapy in Uveal Melanoma

Uveal melanoma (UM) remains without effective therapy at the metastatic stage, which is associated with BAP-1 (BRCA1 associated protein) mutations. However, no data on DNA repair capacities in UM are available. Here, we use UM patient-derived xenografts (PDXs) to study the therapeutic activity of th...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Koning, Leanne, Decaudin, Didier, El Botty, Rania, Nicolas, André, Carita, Guillaume, Schuller, Mathieu, Ouine, Bérengère, Cartier, Aurélie, Naguez, Adnan, Fleury, Justine, Cooke, Vesselina, Wylie, Andrew, Smith, Paul, Marangoni, Elisabetta, Gentien, David, Meseure, Didier, Mariani, Pascale, Cassoux, Nathalie, Piperno-Neumann, Sophie, Roman-Roman, Sergio, Némati, Fariba
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628115/ https://www.ncbi.nlm.nih.gov/pubmed/31146482 http://dx.doi.org/10.3390/cancers11060751

Ejemplares similares

Selumetinib-based therapy in uveal melanoma patient-derived xenografts
por: Decaudin, Didier, et al.
Publicado: (2018)

Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma
por: Carita, Guillaume, et al.
Publicado: (2016)

Patient Derived Xenografts (PDX) Models as an Avatar to Assess Personalized Therapy Options in Uveal Melanoma: A Feasibility Study
por: Nemati, Fariba, et al.
Publicado: (2023)

The mTOR inhibitor Everolimus synergizes with the PI3K inhibitor GDC0941 to enhance anti-tumor efficacy in uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2016)

FAK Inhibitor-Based Combinations with MEK or PKC Inhibitors Trigger Synergistic Antitumor Effects in Uveal Melanoma
por: Tarin, Malcy, et al.
Publicado: (2023)

High in vitro and in vivo synergistic activity between mTORC1 and PLK1 inhibition in adenocarcinoma NSCLC
por: Montaudon, Elodie, et al.
Publicado: (2021)

Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibition
por: El Botty, Rania, et al.
Publicado: (2018)

Multi-omics comparison of malignant and normal uveal melanocytes reveals molecular features of uveal melanoma
por: Gentien, David, et al.
Publicado: (2023)

Targeting Bcl-2/Bcl-X(L) Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
por: Némati, Fariba, et al.
Publicado: (2014)

Upcoming translational challenges for uveal melanoma
por: Nabil, Amirouchene-Angelozzi, et al.
Publicado: (2015)

Upcoming translational challenges for uveal melanoma
por: Amirouchene-Angelozzi, Nabil, et al.
Publicado: (2015)

Phase II Trial of Bevacizumab in Combination With Temozolomide as First-Line Treatment in Patients With Metastatic Uveal Melanoma
por: Piperno-Neumann, Sophie, et al.
Publicado: (2016)

Response to mTOR and PI3K inhibitors in enzalutamide-resistant luminal androgen receptor triple-negative breast cancer patient-derived xenografts
por: Coussy, Florence, et al.
Publicado: (2020)

In vivo efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenografts
por: Passeri, Thibault, et al.
Publicado: (2022)

The Prognostic Values of PARP-1 Expression in Uveal Melanoma
por: Gajdzis, Malgorzata, et al.
Publicado: (2021)

PRMT1 Regulates EGFR and Wnt Signaling Pathways and Is a Promising Target for Combinatorial Treatment of Breast Cancer
por: Suresh, Samyuktha, et al.
Publicado: (2022)

Patient-derived zebrafish xenografts of uveal melanoma reveal ferroptosis as a drug target
por: Groenewoud, Arwin, et al.
Publicado: (2023)

LRP5 regulates the expression of STK40, a new potential target in triple-negative breast cancers
por: Maubant, Sylvie, et al.
Publicado: (2018)

Dramatic In Vivo Efficacy of the EZH2-Inhibitor Tazemetostat in PBRM1-Mutated Human Chordoma Xenograft
por: Passeri, Thibault, et al.
Publicado: (2022)

Preclinical Evaluation of Trabectedin in Combination With Targeted Inhibitors for Treatment of Metastatic Uveal Melanoma
por: Glinkina, Kseniya, et al.
Publicado: (2022)

Cytidine analogs are synthetic lethal with base excision repair default due to MBD4 deficiency
por: Chabot, Thomas, et al.
Publicado: (2022)

Prognostic Implications of MRI Melanin Quantification and Cytogenetic Abnormalities in Liver Metastases of Uveal Melanoma
por: Ramtohul, Toulsie, et al.
Publicado: (2021)

Vasculature analysis of patient derived tumor xenografts using species-specific PCR assays: evidence of tumor endothelial cells and atypical VEGFA-VEGFR1/2 signalings
por: Bieche, Ivan, et al.
Publicado: (2014)

Upregulation of HLA Expression in Primary Uveal Melanoma by Infiltrating Leukocytes
por: van Essen, T. Huibertus, et al.
Publicado: (2016)

The humanized anti-human AMHRII mAb 3C23K exerts an anti-tumor activity against human ovarian cancer through tumor-associated macrophages
por: Bougherara, Houcine, et al.
Publicado: (2017)

Nivolumab plus ipilimumab in metastatic uveal melanoma: a real-life, retrospective cohort of 47 patients
por: Salaün, Hélène, et al.
Publicado: (2022)

Spontaneous mouse lymphoma in patient-derived tumor xenografts: The importance of systematic analysis of xenografted human tumor tissues in preclinical efficacy trials
por: Chateau-Joubert, Sophie, et al.
Publicado: (2021)

So Close, yet so Far: Discrepancies between Uveal and Other Melanomas. A Position Paper from UM Cure 2020
por: Rodrigues, Manuel, et al.
Publicado: (2019)

Protein arginine methyltransferase 5: A novel therapeutic target for triple‐negative breast cancers
por: Vinet, Mathilde, et al.
Publicado: (2019)

Circulating Tumor DNA as a Prognostic Factor in Patients With Resectable Hepatic Metastases of Uveal Melanoma
por: Mariani, Pascale, et al.
Publicado: (2023)

Integrative analysis of multi-platform reverse-phase protein array data for the pharmacodynamic assessment of response to targeted therapies
por: Byron, Adam, et al.
Publicado: (2020)

Angiotropism and extravascular migratory metastasis in cutaneous and uveal melanoma progression in a zebrafish model
por: Fornabaio, Giulia, et al.
Publicado: (2018)

Replacement and desmoplastic histopathological growth patterns: A pilot study of prediction of outcome in patients with uveal melanoma liver metastases
por: Barnhill, Raymond, et al.
Publicado: (2018)

Development of a Prognostic Nomogram for Liver Metastasis of Uveal Melanoma Patients Selected by Liver MRI
por: Mariani, Pascale, et al.
Publicado: (2019)

The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival
por: Dewaele, Shanna, et al.
Publicado: (2021)

Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds
por: Stimmer, Lev, et al.
Publicado: (2014)

PLK1 inhibition exhibits strong anti-tumoral activity in CCND1-driven breast cancer metastases with acquired palbociclib resistance
por: Montaudon, Elodie, et al.
Publicado: (2020)

Genome-wide profiling is a clinically relevant and affordable prognostic test in posterior uveal melanoma
por: Cassoux, Nathalie, et al.
Publicado: (2014)

Correction to: The long non-coding RNA SAMMSON is essential for uveal melanoma cell survival
por: Dewaele, Shanna, et al.
Publicado: (2021)

Outlier response to anti-PD1 in uveal melanoma reveals germline MBD4 mutations in hypermutated tumors
por: Rodrigues, Manuel, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_3cf50ta3efl6o7gfc3q9gnp8p1